REMEGEN

🇭🇰Hong Kong, China

Country: 🇭🇰Hong Kong, China

Ownership: Public

Established: 2008-07-04

Employees: 3.4K

Market Cap: -

Website: http://www.remegen.com

Introduction: The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical va...

Clinical Trials

A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

Phase 1

Completed

Conditions: Unresectable Solid Tumor
Metastatic Solid Tumor
Locally Advanced Solid Tumor

Interventions: Drug: RC118 for injection

First Posted Date: 2021-06-04

Last Posted Date: 2023-06-22

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 7

Registration Number: NCT04914117

Locations: 🇦🇺
Remegen Site #14, Bedford Park, South Australia, Australia
🇦🇺
Remegen Site #12, Macquarie Park, New South Wales, Australia
🇦🇺
Remegen Site #13, Frankston, Victoria, Australia

and more 1 locations

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Phase 2

Terminated

Conditions: IgA Nephropathy

Interventions: Drug: Telitacicept 160mg
Drug: Telitacicept 240mg
Drug: Placebo

First Posted Date: 2021-05-27

Last Posted Date: 2023-12-06

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 15

Registration Number: NCT04905212

Locations: 🇺🇸
Remegen Site #5, Los Angeles, California, United States
🇺🇸
Remegen Site #13, Los Angeles, California, United States
🇺🇸
Remegen Site #14, Los Angeles, California, United States

and more 5 locations

Evaluation of RC28-E Injection in Diabetic Macular Edema

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Biological: intravitreal injection of RC28-E
Biological: Conbercept

First Posted Date: 2021-03-04

Last Posted Date: 2023-12-18

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 156

Registration Number: NCT04782115

Locations: 🇨🇳
People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China
🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China

and more 34 locations

Evaluation of RC28-E Injection in Diabetic Retinopathy

Phase 2

Active, not recruiting

Conditions: Diabetic Retinopathy

Interventions: Biological: RC28-E injection

First Posted Date: 2021-03-04

Last Posted Date: 2023-10-11

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT04782128

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Phase 3

Recruiting

Conditions: Gastric Cancer
HER2 Overexpressing Gastric Carcinoma

Interventions: Drug: RC48-ADC
Drug: Paclitaxel injection
Drug: Irinotecan Hydrochloride Injection
Drug: Apatinib Mesylate Tablets

First Posted Date: 2021-01-19

Last Posted Date: 2023-12-21

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 351

Registration Number: NCT04714190

Locations: 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, China
🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

and more 49 locations

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

Phase 2

Recruiting

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Biological: RC18 240mg
Biological: RC18 160mg

First Posted Date: 2020-11-12

Last Posted Date: 2024-03-18

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT04625153

Locations: 🇨🇳
the Third Affiliated Hospital,Sun Yat-Sen University, Guangzhou, Guangdong, China

A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: RC108

First Posted Date: 2020-11-05

Last Posted Date: 2024-02-20

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT04617314

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China

and more 1 locations

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: RC48-ADC
Drug: Paclitaxel Injection
Drug: Docetaxel Injection
Drug: Vinorelbine Tartrate Injection
Drug: Capecitabine Tablets

First Posted Date: 2020-05-22

Last Posted Date: 2024-01-24

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 366

Registration Number: NCT04400695

Locations: 🇨🇳
Oncology Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer

Phase 2

Active, not recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: RC48-ADC

First Posted Date: 2020-04-01

Last Posted Date: 2023-12-20

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 57

Registration Number: NCT04329429

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
First Hospital of Jilin University, Chang chun, Jilin, China
🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Beijing, China

and more 13 locations

A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: RC48

First Posted Date: 2020-03-17

Last Posted Date: 2023-12-18

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 37

Registration Number: NCT04311034

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy